Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis

Figures & data

Figure 1 PRISMA flowchart of literature search and study selection.

Table 1 Study Characteristics of Included Studies

Author Name	Country	Design	Participants Condition at Baseline	Gender Male/ Female	Mean Age (Years)	Number Randomized in Tezepelumab Group				Number Randomized in Placebo Group	Treatment Duration (Weeks)
						70 mg	210 mg	280 mg	Total
Corren J et al, 2021 (a)^Citation15	Multi	Phase II Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	NR	≥12	138	137	137	412	138	52
Corren J et al, 2021(b)^Citation13	Multi	Phase IIb Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	177/337	51.8	-	128	-	385	130	52
Emson C et al, 2021^Citation17	Multi	Phase IIb Randomized, Double-blind, Placebo-controlled	18 to 75 years old, current non-smokers	93/177	52	-	135	-	135	135	52
Menzies-Gow A et al, 2021^Citation23	Multi	Phase III Randomized, Double-blind, Placebo-controlled	12 to 80 years of age with physician -diagnosed asthma	387/672	49.5	-	528	-	528	531	52
NCT03406078^Citation22	Multi	Phase III Randomized, Double-blind, Placebo-controlled	Patients must have been receiving OCS for at least six months prior screening	56/94	53.4	-	65	-	65	64	52
Diver S et al, 2021^Citation16	Multi	Phase II Randomized, Double-blind, Placebo-controlled	12 to 80 years of age with physician -diagnosed asthma	51/65	50.4	-	59	-	59	57	52

Notes: NR, not reported; mg, milligram.

Figure 2 Assessment of the risk of bias in included studies with Cochrane domain-based quality assessment tool.

Figure 3 Efficacy of tezepelumab versus placebo on FEV₁ based on duration of intervention.

Figure 4 Efficacy of tezepelumab versus placebo on rate of asthma exacerbation based on different doses of intervention.

Figure 5 Efficacy of tezepelumab versus placebo on asthma related quality of life score based on different doses of intervention; Tezepelumab, overall: studies which reported data for combining of all the dosages (70 mg + 210 mg + 280 mg).

Figure 6 Efficacy of tezepelumab versus placebo on blood eosinophil count based on duration of intervention.

Figure 7 Efficacy of tezepelumab versus placebo on FeNO levels based on duration of intervention.

Figure 8 Efficacy of tezepelumab versus placebo on total serum IgE levels based on duration of intervention.

Figure 9 Efficacy of tezepelumab versus placebo on incidence of ADR’s based on different doses of intervention; Tezepelumab, overall: studies which reported data for combining of all the dosages (70 mg + 210 mg + 280 mg).

Corren J, Garcia Gil E, Griffiths JM, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol. 2021;126(2):187–193. doi:10.1016/j.anai.2020.10.008

 PubMed Web of Science ®Google Scholar

Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9(12):4334–42.e6. doi:10.1016/j.jaip.2021.07.045

 PubMed Web of Science ®Google Scholar

Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91–99. doi:10.2147/JAA.S288260

 PubMed Web of Science ®Google Scholar

Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975

 PubMed Web of Science ®Google Scholar

Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). Available from: https://clinicaltrials.gov/ct2/show/NCT03406078. Accessed November 2, 2022.

 Google Scholar

Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5

 PubMed Web of Science ®Google Scholar